Introduction {#section5-2050312118777953}
============

Tobacco use is a risk factor for cardiovascular disease, stroke, cancer, and chronic respiratory diseases and is a major global public health threat.^[@bibr1-2050312118777953],[@bibr2-2050312118777953]^ Guidelines by the US Public Health Service recommend pharmacotherapy to help smokers quit, unless contraindicated.^[@bibr3-2050312118777953]^ The management of withdrawal symptoms is one of the largest problems for smokers trying to quit smoking.^[@bibr4-2050312118777953][@bibr5-2050312118777953]--[@bibr6-2050312118777953]^ Several smoking cessation treatments (SCTs) have been approved by the US Food and Drug Administration (FDA). These include nicotine replacement therapy (NRT) (in the form of transdermal, buccal, oral, respiratory, and nasal administration) and non-nicotine medications such as varenicline and bupropion. The cessation rates with proper usage of SCTs were double compared to those with placebo treatments.^[@bibr7-2050312118777953],[@bibr8-2050312118777953]^ The American Cancer Society (ACS)^[@bibr9-2050312118777953]^ recommends that clinicians advise their patients to use FDA-approved cessation aids that have been proven to be effective.

NRT reduces the motivation to use cigarettes and physical dependence through delivery of nicotine without exposure to harmful combustion products. In general, plasma nicotine concentrations with NRT are lower than those with cigarettes.^[@bibr10-2050312118777953]^ In the case of nicotine patches, the nicotine plasma concentration can become high when the patch is worn for a long time. Oral NRTs such as gum and inhalers deliver nicotine in relatively low levels to the blood. Nasal irritation often produces mild burning, sneezing, stinging, and cough during the initial usage of nicotine nasal spray. Adverse events (AEs) related to nicotine might occur with NRT; however, the differences in AE onset profiles among NRT forms are not clear.

Varenicline is a non-nicotine prescription α~4~β~2~-nicotinic receptor partial agonist that relieves nicotine withdrawal symptoms. Major AEs of varenicline are nausea, abdominal pain, vomiting, headache, and insomnia.^[@bibr8-2050312118777953],[@bibr11-2050312118777953]^ Neuropsychiatric AEs such as depression, anxiety, hallucination, and suicide have been reported. Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and a nicotinic acetylcholine receptor antagonist.^[@bibr12-2050312118777953],[@bibr13-2050312118777953]^ Bupropion reverses the negative effect associated with nicotine withdrawal.^[@bibr14-2050312118777953]^ Insomnia, nausea, vomiting, and dizziness are often reported for bupropion.^[@bibr15-2050312118777953]^

Recently, electronic cigarettes (ECs) and electronic nicotine delivery systems (ENDS) have become a popular nicotine replacement. ECs are battery-powered nicotine delivery systems. Most ECs deliver a nicotine-containing aerosol of ultra-fine particles by heating a solution containing propylene glycol or glycerin, nicotine, flavorings, and other chemicals.^[@bibr16-2050312118777953][@bibr17-2050312118777953]--[@bibr18-2050312118777953]^ However, ECs are not regulated and have not been confirmed as a safe and effective cessation aid. Organizations such as the American Lung Association have expressed concern regarding the potential health risks of ECs and ENDS.^[@bibr19-2050312118777953]^ Major AEs associated with EC use include pneumonia, congestive heart failure, seizures, and tachycardia; minor AEs include respiratory symptoms, headache, eye irritation, nausea, cough, and sore throat/irritation.^[@bibr20-2050312118777953],[@bibr21-2050312118777953]^ A policy statement from the American Heart Association indicated that common minor AEs of ECs include throat and mouth irritation, dry cough, nausea, and vomiting.^[@bibr17-2050312118777953]^ FDA regulatory action supports the need to investigate the AE profiles of ECs. The FDA Center for Tobacco Products (CTP) receives and reviews reports from the Safety Reporting Portal, MedWatch, consumers, and healthcare professionals. The CTP has evaluated AEs associated with e-liquids, EC devices, and exhaled aerosol from ECs and the effects upon non-users exposed to ECs.^[@bibr20-2050312118777953],[@bibr22-2050312118777953]^ The unknown AEs associated with ECs have sparked public health concerns.^[@bibr23-2050312118777953],[@bibr24-2050312118777953]^ However, the relationship between ECs and AEs is still unclear; therefore, we studied the reports of ECs.

Spontaneous reports of AE are used to compile reports of suspected AEs and are available for post-marketing surveillance of products regulated by the regulatory authorities. The Food and Drug Administration Adverse Event Reporting System (FAERS) is the largest and best-known spontaneous reporting system (SRS) database for marketed products, reflecting the realities of clinical practice.^[@bibr25-2050312118777953]^ Cases are reported by clinicians, pharmacists, other healthcare professionals, patients, and the general public to pharmaceutical manufacturers or to the FAERS database. The FAERS database files are openly available on the FDA website.^[@bibr26-2050312118777953]^ Regulatory authorities such as the FDA may take regulatory actions to improve product safety and protect public health based on these data.^[@bibr27-2050312118777953][@bibr28-2050312118777953]--[@bibr29-2050312118777953]^

The purpose of this study was to evaluate the possible relationship among AEs and SCTs and ECs using the FAERS database.

Methods {#section6-2050312118777953}
=======

The FAERS data set from April 2004 to December 2016 that was fully anonymized by the FDA was obtained from the FDA website.^[@bibr26-2050312118777953]^ The informatic structure of the FAERS database is based on the international safety reporting guidelines issued by the International Council on Harmonization (ICH) E2B. We integrated our database from the FAERS data set using FileMaker Pro 13 software (FileMaker, Inc., Santa Clara, CA), according to ASCII Entity Relationship Diagram that is publicly available from the FDA website. AE reports of NRT were extracted using the following keywords: "nicotine," "nicotine (transdermal)," "nicotine (buccal)," or "nicotine (oral)." For varenicline, we used "varenicline," as a generic name together with its trade names "Chantix" and "Champix." For bupropion, we only used its trade name "Zyban" that is used for smoking cessation. AE reports of ECs were extracted using the following keywords: "eliquid," "electric cigarette," "electronic cigarette," "e-cig," "e cig," "electronic nicotine delivery system," "e-pipe," "e-cigar," or "e-hookah." Product reports were further classified into four categories: primary suspect (PS), secondary suspect (SS), concomitant (C), and interacting (I) drugs, according to their anticipated degree of involvement in AEs. For the analysis, we used reports on NRTs, non-nicotine prescription medication, and EC that were recorded as PS. According to the FDA recommendation, we removed duplicate reports from the same patient in the FAERS database from analysis.

Case report counts of AEs were generated according to the preferred terms (PTs) of MedDRA version 19.0, the Medical Dictionary for Regulatory Activities (MedDRA).^[@bibr30-2050312118777953]^ This is a database of standardized medical terminology for medical products and devices.

The reporting odds ratio (ROR), an authorized pharmacovigilance index, was calculated using a disproportionality analysis ([Figure 1](#fig1-2050312118777953){ref-type="fig"}). All reported AEs of interest were defined as "cases" and all reported AEs as "total." The ROR is the ratio of the odds of reporting specific AEs versus all other AEs for a given product, compared with the reporting odds for all other drugs or products present in the database. To compare one of the index groups with the reference group, we calculated the crude RORs as (a:c)/(b:d). RORs were expressed as point estimates with 95% confidence intervals (CIs). The signal is considered significant when the estimated ROR and the lower limit of the 95% CI are \>1.^[@bibr31-2050312118777953]^ Two or more cases were required to define the signal.^[@bibr27-2050312118777953]^

![Two-by-two contingency table for analysis.](10.1177_2050312118777953-fig1){#fig1-2050312118777953}

Data analyses were performed using JMP 12.0 (SAS Institute Inc., Cary, NC, USA).

Results {#section7-2050312118777953}
=======

The FAERS database contained 8,867,135 reports for the period from January 2004 to December 2016. After exclusion of duplicate reports, 7,348,357 reports were usable.

NRT {#section8-2050312118777953}
---

The numbers of AEs for nicotine by transdermal, buccal, oral, and respiratory administration were 1673, 1016, 425, and 56, respectively ([Table 1](#table1-2050312118777953){ref-type="table"}). For transdermal nicotine exposure, top 5 AEs reported were nausea (149 cases, ROR: 2.28 (95% CI: 1.92--2.69)), dizziness (132 cases, ROR: 3.04 (95% CI: 2.54--3.63)), application site erythema (108 cases, ROR: 32.52 (95% CI: 26.74--39.55)), headache (98 cases, ROR: 1.84 (95% CI: 1.50--2.25)), and dyspnea (94 cases, ROR: 1.93 (95% CI: 1.57--2.38)) ([Table 2](#table2-2050312118777953){ref-type="table"}). The numbers of reported cases were drug ineffective (147), treatment noncompliance (128), overdose (87), and product adhesion issue (81), respectively. These reports were not classified as AEs; thus, ROR values were not calculated for these reports.

###### 

Administration route of nicotine.

![](10.1177_2050312118777953-table1)

                              Administration route   Case, n (%)
  --------------------------- ---------------------- -------------
  Total                       7,348,357 (--)         
  Cases related to nicotine   Subtotal               3843 (100)
                              Transdermal            1673 (43.5)
                              Buccal                 1016 (26.4)
                              Oral                   425 (11.1)
                              Respiratory            56 (1.5)
                              Trans-placental        47 (1.2)
                              Nasal                  33 (0.9)
                              Topical                50 (1.3)
                              Sublingual             3 (0.1)
                              Trans-mammary          3 (0.1)
                              Cutaneous              2 (0.1)
                              Unknown                531 (13.8)
                              Other                  4 (0.1)

###### 

Number of reports and reporting odds ratio of AEs and number of reports of other events by nicotine (transdermal).

![](10.1177_2050312118777953-table2)

                       Code       Preferred term              Total^[a](#table-fn2-2050312118777953){ref-type="table-fn"}^ (n)   Case^[b](#table-fn3-2050312118777953){ref-type="table-fn"}^ (n)   Reporting odds ratio (95% CI)
  -------------------- ---------- --------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------- -----------------------------------------------------------
                                                              7,348,357                                                          1673                                                              
  Adverse event (AE)   10028813   Nausea                      302,691                                                            149                                                               2.28 (1.92--2.69)
                       10013573   Dizziness                   201,586                                                            132                                                               3.04 (2.54--3.63)
                       10040943   Application site erythema   15,665                                                             108                                                               32.52 (26.74--39.55)
                       --         Headache                    240,943                                                            98                                                                1.84 (1.50--2.25)
                       10013968   Dyspnea                     219,854                                                            94                                                                1.93 (1.57--2.38)
                       --         Application site pruritus   11,148                                                             92                                                                38.61 (31.26--47.68)
                       --         Malaise                     166,295                                                            81                                                                2.20 (1.76--2.75)
                       10047700   Vomiting                    184,155                                                            79                                                                1.93 (1.54--2.42)
                       --         Insomnia                    123,207                                                            72                                                                2.64 (2.08--3.34)
                       --         Nicotine dependence         5106                                                               62                                                                56.02 (43.40--72.30)
                       10033557   Palpitations                46,754                                                             60                                                                5.82 (4.49--7.53)
                       10016322   Feeling abnormal            99,851                                                             56                                                                2.51 (1.93--3.28)
                       10005750   Blood pressure increased    61,816                                                             53                                                                3.86 (2.93--5.07)
                       --         Abnormal dreams             17,029                                                             49                                                                13.02 (9.8--17.31)
                       10002855   Anxiety                     112,125                                                            48                                                                1.91 (1.43--2.54)
                       --         Application site pain       9238                                                               48                                                                23.58 (17.69--31.45)
  Other                10013709   Drug ineffective            409,995                                                            147                                                               --^[c](#table-fn4-2050312118777953){ref-type="table-fn"}^
                       --         Treatment noncompliance     16,379                                                             128                                                               --^[c](#table-fn4-2050312118777953){ref-type="table-fn"}^
                       10033295   Overdose                    102,021                                                            87                                                                --^[c](#table-fn4-2050312118777953){ref-type="table-fn"}^
                       --         Product adhesion issue      9052                                                               81                                                                --^[c](#table-fn4-2050312118777953){ref-type="table-fn"}^

CI: confidence interval.

Total number of events reported regardless of nicotine (transdermal).

Case number of events associated with nicotine (transdermal).

Not adverse event.

For nicotine (buccal), the top 5 AEs reported were nicotine dependence (138 cases, ROR: 232.29 (95% CI: 193.71--278.56)), nausea (116 cases, ROR: 3.00 (95% CI: 2.47--3.64)), oral discomfort (56 cases, ROR: 75.21 (95% CI: 57.38--98.60)), hiccups (45 cases, ROR: 104.47 (95% CI: 77.33--141.13)), and throat irritation (45 cases, ROR: 20.68 (95% CI: 15.33--27.89)), respectively ([Table 3](#table3-2050312118777953){ref-type="table"}). The numbers of cases were as follows: drug ineffective (143), wrong technique in product usage process (117), intentional drug misuse (52), incorrect dose administered (45), incorrect drug administration duration (40), expired product administered (39), drug administration error (35), and overdose (34).

###### 

Number of reports and reporting odds ratio of AEs and number of reports of other events by nicotine (buccal).

![](10.1177_2050312118777953-table3)

                       Code       Preferred term                             Total^[a](#table-fn6-2050312118777953){ref-type="table-fn"}^ (n)   Case^[b](#table-fn7-2050312118777953){ref-type="table-fn"}^ (n)   Reporting odds ratio (95% CI)
  -------------------- ---------- ------------------------------------------ ------------------------------------------------------------------ ----------------------------------------------------------------- -----------------------------------------------------------
                                                                             7,348,357                                                          1016                                                              
  Adverse event (AE)   --         Nicotine dependence                        5106                                                               138                                                               232.29 (193.71--278.56)
                       10028813   Nausea                                     302,691                                                            116                                                               3.00 (2.47--3.64)
                       10030973   Oral discomfort                            5750                                                               56                                                                75.21 (57.38--98.60)
                       --         Hiccups                                    3303                                                               45                                                                104.47 (77.33--141.13)
                       10043521   Throat irritation                          16,477                                                             45                                                                20.68 (15.33--27.89)
                       10013573   Dizziness                                  201,586                                                            44                                                                1.60 (1.19--2.17)
                       10047700   Vomiting                                   184,155                                                            44                                                                1.76 (1.30--2.38)
                       --         Headache                                   240,943                                                            36                                                                1.08 (0.78--1.51)
                       --         Dyspepsia                                  37,466                                                             32                                                                6.35 (4.47--9.03)
                       10013663   Drug dependence                            15,769                                                             30                                                                14.17 (9.85--20.39)
                       10012735   Diarrhea                                   206,990                                                            29                                                                1.01 (0.70--1.47)
  Other                10013709   Drug ineffective                           409,995                                                            143                                                               --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       10076573   Wrong technique in product usage process   20,980                                                             117                                                               --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       --         Intentional drug misuse                    20,157                                                             52                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       10064355   Incorrect dose administered                55,729                                                             45                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       10064307   Incorrect drug administration duration     21,239                                                             40                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       10074902   Expired product administered               8386                                                               39                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       10064295   Drug administration error                  25,655                                                             35                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       10033295   Overdose                                   102,021                                                            34                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^
                       --         No adverse event                           39,236                                                             33                                                                --^[c](#table-fn8-2050312118777953){ref-type="table-fn"}^

CI: confidence interval.

Total number of events reported regardless of nicotine (buccal).

Case number of events associated with nicotine (buccal).

Not adverse event.

For nicotine (oral), the top 5 AEs reported were dependence (200 cases, ROR: 263.66 (95% CI: 217.84--319.12)), nicotine dependence (133 cases, ROR: 672.55 (95% CI: 546.84--827.15)), drug dependence (41 cases, ROR: 49.78 (95% CI: 36.06--68.71)), dizziness (23 cases, ROR: 2.03 (95% CI: 1.33--3.09)), and nausea (19 cases, ROR: 1.09 (95% CI: 0.69--1.73)), respectively ([Table 4](#table4-2050312118777953){ref-type="table"}). We extracted the PTs for the identification of nicotine (oral)-related AEs such as "dependence," "nicotine dependence," and "drug dependence," which are coded according to the terminology prescribed by the MedDRA. From the Introductory Guide MedDRA Version 19.0, each PT is a distinct descriptor (a single medical concept) for a symptom, sign, disease, diagnosis, therapeutic indication, or medical procedure.^[@bibr32-2050312118777953]^ PTs should be unambiguous and as specific and self-descriptive as possible in the context of international requirements. Therefore, eponymous terms are only used when they are recognized internationally. The granularity/specificity of the PT level is such that clinical pathologic or etiologic qualifiers of the descriptors are represented at the PT level.^[@bibr32-2050312118777953]^ According to ICH E2B, the international safety reporting guidelines, the spontaneous volunteers only report AEs relying on the definitions provided by MedDRA to the FAERS database. Because detailed patient information about "dependence," "nicotine dependence," and "drug dependence" is not intrinsically included in the FAERS database, it was difficult to confirm the exact differences among "dependence," "nicotine dependence," and "drug dependence" reported as PTs by volunteers, even though they are healthcare professionals. Therefore, we separately described each result, but further validation of these associations is needed.

###### 

Number of reports and reporting odds ratio of AEs and number of reports of other events by nicotine (oral).

![](10.1177_2050312118777953-table4)

                       Code       Preferred term                           Total^[a](#table-fn10-2050312118777953){ref-type="table-fn"}^ (n)   Case^[b](#table-fn11-2050312118777953){ref-type="table-fn"}^ (n)   Reporting odds ratio (95% CI)
  -------------------- ---------- ---------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------
                                                                           7,348,357                                                           425                                                                
  Adverse event (AE)   10012335   Dependence                               24,889                                                              200                                                                263.66 (217.84--319.12)
                       --         Nicotine dependence                      5106                                                                133                                                                672.55 (546.84--827.15)
                       10013663   Drug dependence                          15,769                                                              41                                                                 49.78 (36.06--68.71)
                       10013573   Dizziness                                201,586                                                             23                                                                 2.03 (1.33--3.09)
                       10028813   Nausea                                   302,691                                                             19                                                                 1.09 (0.69--1.73)
                       --         Malaise                                  166,295                                                             15                                                                 1.58 (0.94--2.65)
                       --         Headache                                 240,943                                                             12                                                                 0.86 (0.48--1.52)
                       10047700   Vomiting                                 184,155                                                             11                                                                 1.03 (0.57--1.88)
                       10002855   Anxiety                                  112,125                                                             10                                                                 1.56 (0.83--2.91)
                       10012378   Depression                               113,503                                                             10                                                                 1.54 (0.82--2.88)
                       10012735   Diarrhea                                 206,990                                                             10                                                                 0.83 (0.44--1.56)
                       10013968   Dyspnea                                  219,854                                                             10                                                                 0.78 (0.42--1.46)
  Other                --         Intentional drug misuse                  20,157                                                              142                                                                --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       10064307   Incorrect drug administration duration   21,239                                                              40                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       10064295   Drug administration error                25,655                                                              39                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       10033295   Overdose                                 102,021                                                             22                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       10013709   Drug ineffective                         409,995                                                             21                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       --         Product quality issue                    73,438                                                              19                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       10064355   Incorrect dose administered              55,729                                                              13                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^
                       --         Accidental exposure to product           11,458                                                              10                                                                 --^[c](#table-fn12-2050312118777953){ref-type="table-fn"}^

CI: confidence interval.

Total number of events reported regardless of nicotine (oral).

Case number of events associated with nicotine (oral).

Not adverse event.

The numbers of reported cases were as follows: intentional drug misuse (142), incorrect drug administration duration (40), drug administration error (39), overdose (22), drug ineffective (21), product quality issue (19), incorrect dose administered (13), and accidental exposure to product (10).

Non-nicotine prescription medication {#section9-2050312118777953}
------------------------------------

For varenicline, including Chantix and Champix, the numbers of reports for nausea, depression, abnormal dreams, insomnia, and anxiety were 13,038, 8209, 6944, 5256, and 4994, respectively ([Table 5](#table5-2050312118777953){ref-type="table"}). The RORs (95% CI) were as follows: nausea (5.71 (5.60−5.82)), depression (9.42 (9.20−9.65)), abnormal dreams (81.78 (79.24−84.40)), insomnia (5.07 (4.93−5.22)), and anxiety (5.29 (5.14−5.45)).

###### 

Number of reports and reporting odds ratio of AEs and number of reports of other events by varenicline.

![](10.1177_2050312118777953-table5)

                       Code       Preferred term      Total^[a](#table-fn14-2050312118777953){ref-type="table-fn"}^ (n)   Case^[b](#table-fn15-2050312118777953){ref-type="table-fn"}^ (n)   Reporting odds ratio (95% CI)
  -------------------- ---------- ------------------- ------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------
                                                      7,348,357                                                           68,155                                                             
  Adverse event (AE)   10028813   Nausea              302,691                                                             13,038                                                             5.71 (5.60--5.82)
                       10012378   Depression          112,503                                                             8209                                                               9.42 (9.20--9.65)
                       --         Abnormal dreams     17,029                                                              6944                                                               81.78 (79.24--84.40)
                       --         Insomnia            123,207                                                             5256                                                               5.07 (4.93--5.22)
                       10002855   Anxiety             112,125                                                             4994                                                               5.29 (5.14--5.45)
                       10042458   Suicidal ideation   41,024                                                              3983                                                               12.14 (11.74--12.55)
                       10047700   Vomiting            184,155                                                             3978                                                               2.44 (2.36--2.52)
                       --         Headache            240,943                                                             3759                                                               1.73 (1.68--1.79)
                       10016323   Feeling abnormal    99,851                                                              3457                                                               3.98 (3.85--4.12)
                       --         Malaise             166,295                                                             3365                                                               2.27 (2.19--2.35)
                       10013573   Dizziness           201,586                                                             2657                                                               1.44 (1.39--1.50)
                       --         Nightmare           16,546                                                              2626                                                               20.92 (20.05--21.82)
                       --         Fatigue             250,867                                                             2621                                                               1.13 (1.09--1.18)
                       10001488   Aggression          25,547                                                              2514                                                               12.07 (11.57--12.58)
                       --         Suicide attempt     25,434                                                              2036                                                               9.55 (9.12--10.00)
                       --         Irritability        27,648                                                              2026                                                               8.67 (8.29--9.08)
                       --         Constipation        68,744                                                              1999                                                               3.27 (3.12--3.42)
                       10002368   Anger               16,309                                                              1989                                                               15.25 (14.54--15.99)
                       10001497   Agitation           35,623                                                              1960                                                               6.37 (6.09--6.68)
  Other                10013709   Drug ineffective    409,995                                                             3762                                                               --^[c](#table-fn16-2050312118777953){ref-type="table-fn"}^

CI: confidence interval.

Total number of events reported regardless of varenicline.

Case number of events associated with varenicline.

Not adverse event.

For bupropion, the numbers of reports were as follows: insomnia (162), rash (110), anxiety (109), dizziness (102), and convulsion (101), respectively ([Table 6](#table6-2050312118777953){ref-type="table"}). The RORs (95% CI) were as follows: insomnia (6.95 (5.91−8.18)), rash (2.37 (1.95−2.88)), anxiety (4.95 (4.08−6.02)), dizziness (2.53 (2.07−3.10)), and convulsion (7.67 (6.27−9.38)).

###### 

Number of reports and reporting odds ratio of AE and number of reports of other issues by bupropion.

![](10.1177_2050312118777953-table6)

                       Code       Preferred term          Total^[a](#table-fn18-2050312118777953){ref-type="table-fn"}^ (n)   Case^[b](#table-fn19-2050312118777953){ref-type="table-fn"}^ (n)   Reporting odds ratio (95% CI)
  -------------------- ---------- ----------------------- ------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------
                                                          7,348,357                                                           1530                                                               
  Adverse event (AE)   --         Insomnia                123,207                                                             162                                                                6.95 (5.91--8.18)
                       10037844   Rash                    232,341                                                             110                                                                2.37 (1.95--2.88)
                       10002855   Anxiety                 112,125                                                             109                                                                4.95 (4.08--6.02)
                       10013573   Dizziness               201,586                                                             102                                                                2.53 (2.07--3.10)
                       --         Convulsion              67,208                                                              101                                                                7.67 (6.27--9.38)
                       10046735   Urticaria               70,646                                                              99                                                                 7.14 (5.82--8.75)
                       10012378   Depression              112,503                                                             98                                                                 4.40 (3.59--5.41)
                       10001488   Aggression              25,547                                                              93                                                                 18.61 (15.09--22.97)
                       --         Headache                240,943                                                             87                                                                 1.78 (1.43--2.21)
                       10042458   Suicidal ideation       41,024                                                              80                                                                 9.84 (7.86--12.33)
                       --         Hallucination           41,109                                                              76                                                                 9.31 (7.39--11.72)
                       10028813   Nausea                  302,691                                                             73                                                                 1.17 (0.92--1.48)
                       --         Pruritus                180,840                                                             73                                                                 1.99 (1.57--2.51)
                       10016323   Feeling abnormal        99,851                                                              71                                                                 3.53 (2.79--4.49)
                       --         Tremor                  73,257                                                              66                                                                 4.48 (3.50--5.73)
                       --         Malaise                 166,295                                                             59                                                                 1.73 (1.34--2.25)
                       10013968   Dyspnea                 219,854                                                             59                                                                 1.30 (1.00--1.69)
                       --         Loss of consciousness   55,974                                                              58                                                                 5.14 (3.95--6.68)
                       --         Dry mouth               32,669                                                              53                                                                 8.05 (6.12--10.59)
  Other                10013709   Drug ineffective        409,995                                                             71                                                                 --^[c](#table-fn20-2050312118777953){ref-type="table-fn"}^

CI: confidence interval.

Total number of events reported regardless of bupropion.

Case number of events associated with bupropion.

Not adverse event.

ECs {#section10-2050312118777953}
---

For ECs, 27 cases of PS were reported. The numbers of AEs for dizziness and dyspnea were 4 each. The reported numbers of cases of nausea, chest pain, heart rate increased, tremor, disorientation, cough, and wheezing were two for each category. The reported numbers of cases of thermal burn, pulmonary edema, and throat irritation were one for each category. Because ECs are not medication products, we also reviewed other reported terms related to AEs that were not listed in the MedDRA database. The detected terms that were not included in MedDRA were as follows: altered visual depth perception (1), chills (1), device component issue (1), device deposit issue (1), device malfunction (2), device physical property issue (1), fear (1), headache (1), insomnia (1), lung disorder (1), malaise (1), migraine (1), pain (2), product label issue (1), productive cough (1), panic reaction (1), sensation of heaviness (1), and VII^th^ nerve paralysis (1).

Discussion {#section11-2050312118777953}
==========

NRT {#section12-2050312118777953}
---

SCTs generally reduce nicotine withdrawal symptoms that interfere with successful cessation. Nicotine from cigarettes is rapidly absorbed into the pulmonary venous circulation, and the nicotine reaches the brain within seconds.^[@bibr33-2050312118777953]^ Nicotine dependence and abuse liability are influenced by the bioavailability, absorption, distribution, and disposition characteristics of nicotine.^[@bibr34-2050312118777953]^ All forms of NRT are considered to have almost the same efficacy.^[@bibr10-2050312118777953]^ Thus, we compared the AE profile based on the type of NRTs using the FAERS database.

Nicotine (transdermal, buccal, and oral) caused AEs such as nausea, nicotine dependence, and dizziness, which might have been caused by nicotine in our study. The RORs of nicotine (buccal) and nicotine (oral) were higher than those of nicotine (transdermal). Based on real-world FAERS data, we considered that the risk of nicotine dependency related to oral or buccal formulas should not be underestimated. When the patient uses transdermal nicotine in the morning, the nicotine level slowly increases over many hours. If a 24-h nicotine patch applied at night causes insomnia or unpleasant dreams, the patch can be removed at bedtime. Although several transdermal nicotine formulations with tapering dosages are available, clinical trials have not demonstrated the effect of smoking cessation by tapering.^[@bibr35-2050312118777953]^ It is reported that because buccal nicotine formulations have a slow absorption rate and are subject to a first-pass effect, they may be associated with lower dependence. Because oral NRT formulations deliver relatively lower nicotine levels, oral NRT formulations require multiple administrations per day to reduce withdrawal symptoms.

Compliance with recommended NRT use was highest for patches, lower for gum, and very low for sprays and inhalers.^[@bibr10-2050312118777953]^ The RORs of application site edema and application site pruritus were high. These AE-related application sites might cause a problem of treatment noncompliance. Clinicians should pay attention to cutaneous symptoms. Furthermore, the RORs of oral discomfort and throat irritation were high. These AEs also might decrease patient compliance.

In particular, we should not ignore the risk of misuse of NRTs, regardless of the route of administration (transdermal, buccal, and oral). Many cases of improper use have been reported, such as nicotine overdose for transdermal nicotine; wrong technique in product usage process, intentional drug misuse, incorrect dose administered, incorrect drug administration duration, expired product administered, and drug administration error for buccal nicotine; and intentional drug misuse, incorrect drug administration duration, drug administration error, and overdose for oral nicotine. Healthcare professionals should closely monitor the methods of use of NRT by smokers attempting cessation to prevent misuse.

Non-nicotine prescription medication {#section13-2050312118777953}
------------------------------------

Nausea, depression, abnormal dreams, and insomnia have been reported for varenicline ([Table 5](#table5-2050312118777953){ref-type="table"}). We observed that the reported numbers of abnormal dreams and nightmares were ranked in the top 12 and the RORs of both AEs were high (81.78 for abnormal dreams, 20.92 for nightmare) for varenicline ([Table 5](#table5-2050312118777953){ref-type="table"}). However, these AEs were not listed in the top 19 AEs for bupropion ([Table 6](#table6-2050312118777953){ref-type="table"}). The causal relationship between varenicline and these neuropsychiatric AEs is not settled.

Safety concerns regarding the potential for an increased risk of serious cardiovascular AEs for varenicline were demonstrated by a meta-analysis.^[@bibr36-2050312118777953]^ Another meta-analysis showed no significant increase in serious cardiovascular AEs.^[@bibr37-2050312118777953]^ We did not observe cardiovascular AEs in the top 20 AEs associated with varenicline ([Table 5](#table5-2050312118777953){ref-type="table"}).

For bupropion, the commonly reported AEs were insomnia, nausea/vomiting, and dizziness in a post-marketing observational cohort study.^[@bibr15-2050312118777953]^ There was no evidence of an increase in all-cause mortality up to 12 weeks after starting bupropion.^[@bibr15-2050312118777953]^ The occurrence rate of seizures was approximately 0.1%.^[@bibr13-2050312118777953]^

Moore et al.^[@bibr38-2050312118777953]^ reported suicidal behavior and depression in SCTs using the FAERS database. Varenicline showed a statistically significant increased risk of depression and suicidality. Bupropion had relatively smaller increased risks.^[@bibr38-2050312118777953]^ We also listed suicidal ideation and suicide attempts with varenicline and bupropion ([Table 5](#table5-2050312118777953){ref-type="table"} and [6](#table6-2050312118777953){ref-type="table"}). In contrast, suicidality risks did not appear to show a significant increase associated with use of any specific smoking cessation pharmacotherapy.^[@bibr39-2050312118777953]^ Cigarette smoking itself is considered a predictor of suicidal acts.^[@bibr35-2050312118777953],[@bibr40-2050312118777953]^ Given these conflicting data, we considered that the evaluation of the suicidality risk for SCT is difficult.

Recently, based on the phase 4 randomized, double-blind EAGLES trial,^[@bibr41-2050312118777953]^ the FDA revised the description of mental health side effects related to mood, behavior, and thinking with varenicline and bupropion to be lower than previously suspected and removed the warning on the box and updated the warning section for both drugs.^[@bibr42-2050312118777953]^ The results of the trial confirm that the benefits of smoking cessation outweigh the risks of these non-nicotine prescription medications.

It is important to note that our results do not justify not using non-nicotine prescription medication because the benefits and safety of these drugs have been accepted worldwide.

ECs {#section14-2050312118777953}
---

We observe EC-related AEs such as dizziness, dyspnea, nausea, heart rate increased, and tremor. Some studies have found no increase in heart rate with EC use.^[@bibr43-2050312118777953][@bibr44-2050312118777953]--[@bibr45-2050312118777953]^ Some studies reported that short-term vaping of ECs resulted in increased heart rate in EC-naive smokers.^[@bibr46-2050312118777953],[@bibr47-2050312118777953]^ ECs containing nicotine may increase heart rate and blood pressure because of systemic absorption of nicotine. However, nicotine content, constituents, and toxicant levels in ECs vary based on solution formulation and the design of the device.^[@bibr48-2050312118777953][@bibr49-2050312118777953]--[@bibr50-2050312118777953]^ Furthermore, in several studies, plasma concentrations of nicotine from ECs were lower than concentrations in conventional cigarettes.^[@bibr44-2050312118777953],[@bibr51-2050312118777953]^ As the exact brands of ECs were not included in the FAERS reports, we have no information on the concentrations of nicotine involved. Prescribers and users of ECs should carefully monitor cardiovascular events.

We found reports on respiratory, thoracic, and mediastinal disorders, including wheezing, cough, and pulmonary edema. The effect of ECs on respiratory and thoracic functions cannot be ignored. The health effects of ECs should be evaluated in terms of the constituents of EC aerosols and their known toxicities.^[@bibr16-2050312118777953],[@bibr52-2050312118777953],[@bibr53-2050312118777953]^ Propylene glycol and glycerin are the base ingredients of the EC solution.^[@bibr50-2050312118777953]^ Propylene glycol exposure causes respiratory and eye irritation.^[@bibr16-2050312118777953],[@bibr54-2050312118777953]^ When heated and vaporized, propylene glycol and glycerol form propylene oxide and acrolein, respectively, which can cause upper respiratory tract irritation.^[@bibr55-2050312118777953]^ Respiratory irritation and bronchial constriction might be caused by propylene glycol aerosols, raising concerns about harm to individuals with asthma and chronic obstructive pulmonary disease. There have been case reports of lung disease caused by ECs.^[@bibr56-2050312118777953][@bibr57-2050312118777953]--[@bibr58-2050312118777953]^ Polosa et al.,^[@bibr59-2050312118777953][@bibr60-2050312118777953]--[@bibr61-2050312118777953]^ however, reported that smokers with asthma and chronic obstructive pulmonary disease saw an improvement in symptoms after switching from conventional cigarettes to ECs.

In a clinical trial of long-term EC use, lower rates of AEs were reported from the use of nicotine patches than from the use of conventional cigarettes.^[@bibr62-2050312118777953]^ Another study found no significant differences in AEs between ECs and nicotine patches.^[@bibr63-2050312118777953]^

Smoking conventional cigarettes exposes smokers to harmful and potentially harmful constituents that contain thousands of chemicals and can cause serious diseases.^[@bibr64-2050312118777953],[@bibr65-2050312118777953]^ In line with the current tobacco harm reduction strategy, the toxicity of ECs should be determined relative to the known toxicity of conventional cigarettes.^[@bibr17-2050312118777953]^

The ACS recently released a statement supporting EC use for certain groups. There are smokers not considering quitting smoking and also smokers who do not use FDA-approved SCTs despite clinician advice. For these individuals, switching to exclusive use of the least harmful form of tobacco products such as ECs is preferable to continuing to smoke combustible tobacco products.^[@bibr9-2050312118777953]^ Of course, the ACS^[@bibr9-2050312118777953]^ has emphasized that these individuals should be regularly advised to completely quit using all tobacco products such as combustible tobacco and ECs.

One case of a thermal burn was reported in our study. However, the FDA has indicated that at least four reports on burn injuries from ENDS have been published.^[@bibr66-2050312118777953],[@bibr67-2050312118777953]^ The FAERS data set may not have corresponded with the CTP or other clinical reports. However, information from these data sets might be considered of complementary value.

Limitations {#section15-2050312118777953}
===========

Because the FAERS database is subject to various biases, including under-reporting, event misclassification, the lack of a clear denominator (healthy individuals), and possible confounding factors, the RORs offer only a rough indication of the signal strength. The prevalence of reported AEs is influenced by several factors, including smoking status and health history. Because detailed information on the background of relevant persons is not included in the FAERS database, findings should be interpreted with caution. Causality was not established for any of the AEs and cases discussed, and some may be related to preexisting patient history and medical conditions. Therefore, robust epidemiological studies are recommended.

The FAERS database is the largest primary data tool available to the FDA for post-marketing drug AE surveillance and represents an opportunity to interrogate data that reflect the realities of clinical practice. Our results strengthen the already-available evidence, and we consider that our supportive and equivalent results will further add to the existing knowledge.

Conclusion {#section16-2050312118777953}
==========

We first evaluated the association between AE and SCTs and ECs using the FAERS database. NRTs such as transdermal, buccal, and oral nicotine caused AEs such as nausea, nicotine dependence, and dizziness. As many cases of improper use of NRTs have been reported, healthcare professionals should closely monitor smokers attempting smoking cessation for the misuse of NRTs. Nausea, depression, abnormal dreams, insomnia, and other AEs have been reported for varenicline. Insomnia, rash, anxiety, and dizziness have been reported for bupropion. We observed EC-related AEs such as dizziness, dyspnea, nausea, heart rate increased, and tremor. These findings may be informative to healthcare professionals in order to improve the management of SCT.
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